Hypermarcas (OTCMKTS:HYPMY) Sets New 1-Year Low - Time to Sell?

Key Points

• Hypermarcas shares plunged to a new 52-week low of $3.39, down from the prior close of $5.40, amid 31,720 shares traded.
• Despite the selloff, analyst sentiment remains positive: Jefferies upgraded the stock to “Strong Buy,” while the overall analyst consensus is “Buy,” based on one Strong Buy and one Hold rating.
• The company recently exceeded quarterly earnings expectations, reporting $0.14 EPS versus a $0.13 consensus; it has a 19.77% net margin and analysts project $0.51 EPS for the current fiscal year.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) shares hit a new 52-week low during mid-day trading on Monday. The stock traded as low as $3.39 and last traded at $3.39, with a volume of 31,720 shares traded. The stock had previously closed at $5.40.

Analyst Ratings Changes

Separately, Jefferies Financial Group upgraded shares of Hypermarcas to a "strong-buy" rating in a research note on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy".

Hypermarcas Price Performance

The stock has a market cap of $2.75 billion, a price-to-earnings ratio of 7.80 and a beta of 0.65. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.86 and a quick ratio of 1.26. The stock's 50 day simple moving average is $4.68 and its two-hundred day simple moving average is $4.44.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. On average, analysts forecast that Hypermarcas will post 0.51 earnings per share for the current fiscal year.

About Hypermarcas

Hypermarcas SA was a Brazilian consumer-health and pharmaceutical company that later changed its corporate name to Hypera SA The company was established as a diversified consumer-products business and, over time, shifted its focus toward pharmaceuticals and healthcare products.

Hypera develops, manufactures and markets prescription medicines, generic and branded-generic drugs, over-the-counter products, vitamins and nutritional supplements. Its portfolio has included well-known Brazilian consumer-health brands such as Neosaldina, Doril, Engov, Benegrip and Addera D3, serving categories including pain relief, cold and flu treatment, digestive health and vitamins.

The company's principal market is Brazil, where its products are distributed through pharmacies, retailers and other healthcare channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.